Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.65 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.65 |
| ▸ | BCHE | P06276 | 9/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5098479 | 0.92 | BCHE (0.65) | PDCD1CD274BCHEMEN1KMT2A | |
| SCHEMBL8519393 | 0.87 | BCHE (0.63) | BCHEMEN1KMT2AMAOB | |
| SCHEMBL5105375 | 0.87 | BCHE (0.65) | PDCD1CD274BCHEMAOB | |
| SCHEMBL6381611 | 0.85 | KMT2A (0.63) | PDCD1CD274MEN1KMT2A | |
| SCHEMBL5105167 | 0.84 | S1PR1 (0.60) | PDCD1CD274BCHEMEN1KMT2A | |
| SCHEMBL5105396 | 0.84 | CD274 (0.66) | PDCD1CD274MEN1KMT2AMAOB | |
| SCHEMBL7370246 | 0.83 | DPP7 (0.57) | BCHE | |
| SCHEMBL2036022 | 0.83 | LMNA (0.66) | BCHEMEN1KMT2AMAOB | |
| SCHEMBL5105462 | 0.83 | KDM4E (0.55) | PDCD1CD274MEN1KMT2A | |
| SCHEMBL15201156 | 0.83 | NOX1 (0.60) | BCHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7411091-B2 | N-acyl-N′-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2008-08-12 | — | — | US | claimed |
| EP-1689708-B1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARM SPA (IT) | 2007-06-27 | — | — | EP | claimed |
| US-20070142455-A1 | N-acyl-n'-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-21 | — | — | US | claimed |
| CN-1886370-A | N-acyl-N' -benzyl-alkylenediamino derivatives | NEWRON PHARM SPA (IT) | 2006-12-27 | — | — | CN | claimed |
| EP-1689708-A1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-16 | — | — | EP | claimed |
| WO-2005054189-A1 | N-ACYL-N'-BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | claimed |
| EP-1535908-A1 | N-acyl-N'-benzyl-alkylendiamino drivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-06-01 | — | — | EP | claimed |
| US-7411091-B2 | N-acyl-N′-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2008-08-12 | — | — | US | disclosed |
| EP-1689708-B1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARM SPA (IT) | 2007-06-27 | — | — | EP | disclosed |
| US-20070142455-A1 | N-acyl-n'-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| CN-1886370-A | N-acyl-N' -benzyl-alkylenediamino derivatives | NEWRON PHARM SPA (IT) | 2006-12-27 | — | — | CN | disclosed |
| EP-1689708-A1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054189-A1 | N-ACYL-N'-BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | disclosed |
| EP-1535908-A1 | N-acyl-N'-benzyl-alkylendiamino drivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142455-A1 | N-acyl-n'-benzyl-alkylendiamino derivatives | SCN7A, HTR7, TRPC7 | PDCD1 4832/4885CD274 4861/4885BCHE 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.